New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
About this episode
Hope S. Rugo discusses the evolving landscape of breast cancer treatment and decision-making in light of new therapies.
“In breast cancer now, all of our treatment for hormone receptor–positive metastaticdisease is a bit of a moving target because of new therapies that are available,”explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women’sCancers Program director at the City of Hope Comprehensive Cancer Center in Duarte,California. She discusses the “ever-changing” landscape involving the PI3kinase/AKT/mTOR pathway with Robert A. Figlin, MD, the Steven Spielberg FamilyChair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. Dr. Rugo detailskey considerations that she uses for decision making in practice. “And I think we justwant to be cautious about toxicity for these patients and really know that we’rebenefiting them, rather than using up treatments,” she explains.
More episodes of Oncology News Central Peer-Spectives
- Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
- Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
- Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
- “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
- “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
- As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?
Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.